CANbridge Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

BEIJING & SHANGHAI

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James Xue, Ph.D., Founder, Chairman and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 10:30 AM Pacific Time. Dr. Xue will give an overview of the company, including recent development program and rare disease portfolio updates.

A live webcast can be accessed by JPM website: https://events.jpmorgan.com/

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. is a China-based biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.

CANbridge has been widely recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In addition, it has an exclusive licensing agreement to commercialize Hunterase™, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib), approved in the US, and rights to other novel candidates.

For more on CANbridge Pharmaceuticals Inc., please go to www.canbridgepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005800/en/